πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 169 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12403183

Factor VIII polypeptide formulations

BIOVERATIV THERAPEUTICS INC. Β· Granted Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12403164

Lentiviral vector formulations

BIOVERATIV THERAPEUTICS INC. Β· Granted Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12391750

Anti-C1S antibodies and methods of use thereof

Bioverativ USA Inc. Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12371747

Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VI

BIOVERATIV THERAPEUTICS INC. Β· Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12364774

Nucleic acid molecules and uses thereof for non-viral gene therapy

BIOVERATIV THERAPEUTICS INC. Β· Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12268688

Compositions and methods of use for modified release minoxidil

Veradermics Incorporated Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12257288

Methods of inducing immune tolerance to clotting factors

BIOVERATIV THERAPEUTICS INC. Β· Granted Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12240917

Anti-complement C1s antibodies and uses thereof

Bioverativ USA Inc. Β· Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12215169

Anti-complement C1s antibodies and uses thereof

Bioverativ USA Inc. Β· Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12201639

Aqueous oral pharmaceutical suspension compositions

ReveraGen BioPharma, Inc. Β· Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12186375

Factor VIII chimeric and hybrid polypeptides, and methods of use thereof

BIOVERATIV THERAPEUTICS INC. Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12173307

Methods for the purification of viral vectors

BIOVERATIV THERAPEUTICS INC. Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12161696

Methods of treating hemophilic arthropathy using chimeric clotting factors

BIOVERATIV THERAPEUTICS INC. Β· Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12128092

Lyophilized factor IX formulations

BIOVERATIV THERAPEUTICS INC. Β· Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12059400

Medical compound

VERA SALUS RICERCA S.R.L. Β· Granted Tue Aug 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12030925

Methods of treating hemophilia A

BIOVERATIV THERAPEUTICS INC. Β· Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12005220

Microneedle patch for immunostimulatory drug delivery

Veradermics Incorporated Β· Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11976329

Methods and systems for detecting usual interstitial pneumonia

Veracyte, Inc. Β· Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11877989

Nutritional supplement containing L-Ξ±-glycerophosphorylcholine

Energy Beverages LLC Β· Granted Tue Jan 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11873296

Solid forms of a dual RAF/MEK inhibitor

VERASTEM, INC. Β· Granted Tue Jan 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11833159

Non-hormonal steroid modulators of NF-kB for treatment of disease

ReveraGen BioPharma, Inc. Β· Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11753461

Optimized factor VIII genes

BIOVERATIV THERAPEUTICS INC. Β· Granted Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11718576

Compositions and methods comprising resveratrol

Biocogent, LLC Β· Granted Tue Aug 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11690851

Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes,

The Board of Regents of the University of Texas System Β· Granted Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted